2022
Endovascular fenestration and iliac stenting for acute limb ischemia caused by type B aortic dissection
Satam K, Alameddine D, Aboian E, Fischer U, Guzman R, Chaar C. Endovascular fenestration and iliac stenting for acute limb ischemia caused by type B aortic dissection. Journal Of Vascular Surgery Cases And Innovative Techniques 2022, 9: 101077. PMID: 36923164, PMCID: PMC10009714, DOI: 10.1016/j.jvscit.2022.11.014.Peer-Reviewed Original ResearchAcute limb ischemiaRight common iliac arteryType B aortic dissectionB aortic dissectionCommon iliac arteryLimb ischemiaAortic dissectionIliac arteryLower extremity symptomsEndovascular fenestrationChest painReperfusion strategyDissection flapExtremity symptomsAorta sizeRight legIschemiaDissectionFlapArteryFenestrationStentsMinimal increaseReinterventionPainEmergency department initiated resuscitative endovascular balloon occlusion of the aorta (REBOA) for out‐of‐hospital cardiac arrest is feasible and associated with improvements in end‐tidal carbon dioxide
Daley J, Buckley R, Kisken KC, Barber D, Ayyagari R, Wira C, Aydin A, Latich I, Lozada JCP, Joseph D, Marino A, Mojibian H, Pollak J, Chaar CO, Bonz J, Belsky J, Coughlin R, Liu R, Sather J, Van Tonder R, Beekman R, Fults E, Johnson A, Moore C. Emergency department initiated resuscitative endovascular balloon occlusion of the aorta (REBOA) for out‐of‐hospital cardiac arrest is feasible and associated with improvements in end‐tidal carbon dioxide. Journal Of The American College Of Emergency Physicians Open 2022, 3: e12791. PMID: 36176506, PMCID: PMC9463569, DOI: 10.1002/emp2.12791.Peer-Reviewed Original ResearchAdvanced cardiac life supportResuscitative endovascular balloon occlusionEnd-tidal carbon dioxideHospital cardiac arrestEndovascular balloon occlusionAortic occlusionCardiac life supportOHCA patientsBalloon occlusionCardiac arrestEmergency departmentLife supportAcademic urban EDEarly feasibility trialUrban ED settingIntra-aortic balloonTidal carbon dioxideReperfusion strategyHospital admissionSpontaneous circulationUrban EDED settingFeasibility trialBalloon deflationChest compressions
2016
Fibrinolytic therapy in hospitals without percutaneous coronary intervention capabilities in China from 2001 to 2011: China PEACE-retrospective AMI study
Li J, Li X, Ross JS, Wang Q, Wang Y, Desai NR, Xu X, Nuti SV, Masoudi FA, Spertus JA, Krumholz HM, Jiang L, Group F. Fibrinolytic therapy in hospitals without percutaneous coronary intervention capabilities in China from 2001 to 2011: China PEACE-retrospective AMI study. European Heart Journal Acute Cardiovascular Care 2016, 6: 232-243. PMID: 26787648, DOI: 10.1177/2048872615626656.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionElevation myocardial infarctionFibrinolytic therapyMyocardial infarctionPercutaneous coronary intervention capabilitySequential cross-sectional studiesChina PEACE-Retrospective AMI StudyPrimary reperfusion strategyPercutaneous coronary interventionLittle clinical evidenceCross-sectional studyQuality of careTwo-stage random samplingCoronary interventionHospital delayNeedle timeReperfusion strategySymptom onsetTherapy useClinical evidenceEmergency departmentMedian admissionIdeal patientPatientsWeighted proportion
2015
Sex Differences in Reperfusion in Young Patients With ST-Segment–Elevation Myocardial Infarction
D'Onofrio G, Safdar B, Lichtman JH, Strait KM, Dreyer RP, Geda M, Spertus JA, Krumholz HM. Sex Differences in Reperfusion in Young Patients With ST-Segment–Elevation Myocardial Infarction. Circulation 2015, 131: 1324-1332. PMID: 25792558, PMCID: PMC4652789, DOI: 10.1161/circulationaha.114.012293.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionMyocardial infarctionReperfusion therapyAcute ST-segment elevation myocardial infarctionProspective observational cohort studyYoung AMI Patients (VIRGO) studyTime guidelinesYoung womenObservational cohort studyProportion of patientsElevation myocardial infarctionPercutaneous coronary interventionYears of ageSex differencesPatients 18Reperfusion strategyCohort studyCoronary interventionFibrinolytic therapyNeedle timeYounger patientsReperfusion delayRatio of womenReperfusion guidelinesSex disparities
2013
Clinical implications of the angiosome model in peripheral vascular disease
Sumpio BE, Forsythe RO, Ziegler KR, van Baal JG, Lepantalo MJ, Hinchliffe RJ. Clinical implications of the angiosome model in peripheral vascular disease. Journal Of Vascular Surgery 2013, 58: 814-826. PMID: 23972249, DOI: 10.1016/j.jvs.2013.06.056.Peer-Reviewed Original ResearchConceptsPeripheral vascular diseaseVascular diseaseAngiosome modelVascular surgeryCritical limb ischemiaLarger patient populationReperfusion strategyProspective trialRevascularization attemptsSuccessful revascularizationLimb ischemiaSecondary amputationProspective studyFluorescent angiographyPatient populationVascular operationsAngiosome conceptEndovascular proceduresUnhealed woundsSystematic reviewClinical implicationsDiseaseSurgeryCurrent literatureSignificant rate
2012
Reperfusion Strategies and Quality of Care in 5339 Patients Age 80 Years or Older Presenting With ST‐Elevation Myocardial Infarction: Analysis from Get With The Guidelines‐Coronary Artery Disease
Medina H, Cannon C, Fonarow G, Grau‐Sepulveda M, Hernandez A, Peacock W, Laskey W, Peterson E, Schwamm L, Bhatt D, Committee and Investigators O. Reperfusion Strategies and Quality of Care in 5339 Patients Age 80 Years or Older Presenting With ST‐Elevation Myocardial Infarction: Analysis from Get With The Guidelines‐Coronary Artery Disease. Clinical Cardiology 2012, 35: 632-640. PMID: 22744844, PMCID: PMC6652419, DOI: 10.1002/clc.22036.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAged, 80 and overAngioplasty, Balloon, CoronaryAntihypertensive AgentsConfidence IntervalsCoronary Artery DiseaseFemaleFibrinolytic AgentsHospital MortalityHumansHypolipidemic AgentsMaleMyocardial InfarctionMyocardial ReperfusionOdds RatioPlatelet Aggregation InhibitorsPractice Guidelines as TopicQuality of Health CareRegistriesThrombolytic TherapyConceptsPrimary percutaneous coronary interventionHospital mortalityReperfusion strategyNR patientsPatient ageUse of PCIGuidelines-Coronary Artery Disease databaseGuidelines-Coronary Artery DiseasePatients age 80 yearsST-elevation myocardial infarctionLower body mass indexGWTG-CAD hospitalsMain reperfusion strategyProportion of patientsPercutaneous coronary interventionAge 80 yearsBody mass indexLength of stayEvidence-based therapiesQuality of carePPCI patientsUnderwent thrombolysisHospital outcomesOld presentingRenal insufficiency
2010
Impact of Transfer for Primary Percutaneous Coronary Intervention on Survival and Clinical Outcomes (from the HORIZONS-AMI Trial)
Wöhrle J, Desaga M, Metzger C, Huber K, Suryapranata H, Guetta V, Guagliumi G, Witzenbichler B, Parise H, Mehran R, Stone G. Impact of Transfer for Primary Percutaneous Coronary Intervention on Survival and Clinical Outcomes (from the HORIZONS-AMI Trial). The American Journal Of Cardiology 2010, 106: 1218-1224. PMID: 21029816, DOI: 10.1016/j.amjcard.2010.06.049.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAnticoagulantsChi-Square DistributionCoronary AngiographyFemaleHeparinHirudinsHumansMaleMiddle AgedMyocardial InfarctionPatient TransferPeptide FragmentsProportional Hazards ModelsProspective StudiesRecombinant ProteinsStatistics, NonparametricSurvival RateTime FactorsTreatment OutcomeConceptsPrimary percutaneous coronary interventionPrimary PCIST-segment elevation myocardial infarctionHORIZONS-AMI trialPercutaneous coronary interventionClinical outcomesCoronary interventionGlycoprotein IIb/IIIa inhibitorsMajor adverse cardiac eventsNet adverse clinical eventsIIb/IIIa inhibitorsAdverse cardiac eventsAdverse clinical eventsElevation myocardial infarctionPreferred reperfusion strategyPresentation of patientsInterventional hospitalMajor bleedingReperfusion strategyBalloon timeCardiac eventsCardiac deathPCI centerUnfractionated heparinMedian time
2009
Choice of Reperfusion Strategy at Hospitals With Primary Percutaneous Coronary Intervention
Fazel R, Krumholz HM, Bates ER, French WJ, Frederick PD, Nallamothu BK. Choice of Reperfusion Strategy at Hospitals With Primary Percutaneous Coronary Intervention. Circulation 2009, 120: 2455-2461. PMID: 19948977, DOI: 10.1161/circulationaha.109.860544.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionElevation myocardial infarctionPCI-capable hospitalsPrimary PCIReperfusion strategyMyocardial infarctionFibrinolytic therapySystem-related factorsPercutaneous coronary intervention capabilityMyocardial Infarction (TIMI) risk scorePrimary percutaneous coronary interventionHierarchical multivariable logistic regressionKey clinical factorsPercutaneous coronary interventionMultivariable logistic regressionPCI useCardiogenic shockCoronary interventionClinical factorsIntracranial hemorrhageNonwhite raceNational registryRisk factorsAdvanced ageFemale gender
2007
Impact of Delay in Door-to-Needle Time on Mortality in Patients With ST-Segment Elevation Myocardial Infarction
McNamara RL, Herrin J, Wang Y, Curtis JP, Bradley EH, Magid DJ, Rathore SS, Nallamothu BK, Peterson ED, Blaney ME, Frederick P, Krumholz HM. Impact of Delay in Door-to-Needle Time on Mortality in Patients With ST-Segment Elevation Myocardial Infarction. The American Journal Of Cardiology 2007, 100: 1227-1232. PMID: 17920362, PMCID: PMC2715362, DOI: 10.1016/j.amjcard.2007.05.043.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overArrhythmias, CardiacCaliforniaCohort StudiesEmergency Service, HospitalEmergency TreatmentFemaleFibrinolytic AgentsHospital MortalityHumansMaleMedical RecordsMyocardial InfarctionOutcome Assessment, Health CareRegistriesRetrospective StudiesThrombolytic TherapyTime and Motion StudiesTime FactorsConceptsST-segment elevation myocardial infarctionElevation myocardial infarctionNeedle timeFibrinolytic therapyMyocardial infarctionHospital mortalitySymptom onsetOdds ratioReperfusion strategyAdjunctive medicationsHospital arrivalShorter doorTimely administrationNational registryRepresentative cohortPatientsMortalityInfarctionTherapyIndependent effectsCohortMinutesSmaller centersOnsetImpact of delayAcute Coronary Care in the Elderly, Part II
Alexander KP, Newby LK, Armstrong PW, Cannon CP, Gibler WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM, Ohman EM. Acute Coronary Care in the Elderly, Part II. Circulation 2007, 115: 2570-2589. PMID: 17502591, DOI: 10.1161/circulationaha.107.182616.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAge FactorsAgedAged, 80 and overAngina, UnstableAngioplasty, Balloon, CoronaryCardiovascular AgentsClinical Trials as TopicCombined Modality TherapyDisease ManagementDisease SusceptibilityEvidence-Based MedicineFemaleFibrinolytic AgentsGeriatricsHumansMaleMiddle AgedMulticenter Studies as TopicMyocardial InfarctionMyocardial RevascularizationPatient RightsPractice Guidelines as TopicPrejudiceQuality of LifeRegistriesRisk FactorsStentsThrombolytic TherapyTreatment OutcomeConceptsST-segment elevation myocardial infarctionElderly patientsMyocardial infarctionInvasive treatmentAmerican Heart Association scientific statementOlder adultsComplex health statusGuideline-recommended careTreatment-associated risksAcute coronary syndromeAcute coronary careTreatment-related benefitsAge 85 yearsPatient-centered mannerQuality of lifeLimited trial dataCoronary syndromeReperfusion strategyAbsolute contraindicationAdjunctive therapyCardiovascular medicationsOlder patientsCoronary careGeriatric conditionsElderly subgroup
2004
Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction
Costantini CO, Stone GW, Mehran R, Aymong E, Grines CL, Cox DA, Stuckey T, Turco M, Gersh BJ, Tcheng JE, Garcia E, Griffin JJ, Guagliumi G, Leon MB, Lansky AJ. Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. Journal Of The American College Of Cardiology 2004, 44: 305-312. PMID: 15261923, DOI: 10.1016/j.jacc.2004.03.058.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionIIb/IIIa inhibitorsTissue-level perfusionMyocardial perfusionPrimary angioplastyMyocardial infarctionGlycoprotein IIb/IIIa inhibitionGlycoprotein IIb/IIIa inhibitorsGP IIb/IIIa inhibitorsClinical implicationsIIb/IIIa inhibitionSimilar long-term mortalityLarge-scale prospective studiesMechanical reperfusion strategiesLong-term mortalityMyocardial blush gradeMinority of patientsNormal myocardial perfusionDistinct risk categoriesBlush gradePrimary PCIReperfusion strategyMyocardial reperfusionBalloon angioplastyPrognostic importanceImportance of mitral regurgitation inpatients undergoing percutaneous coronaryintervention for acute myocardial infarction The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial
Pellizzon GG, Grines CL, Cox DA, Stuckey T, Tcheng JE, Garcia E, Guagliumi G, Turco M, Lansky AJ, Griffin JJ, Cohen DJ, Aymong E, Mehran R, O'Neill WW, Stone GW. Importance of mitral regurgitation inpatients undergoing percutaneous coronaryintervention for acute myocardial infarction The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. Journal Of The American College Of Cardiology 2004, 43: 1368-1374. PMID: 15093869, DOI: 10.1016/j.jacc.2003.11.046.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalFemaleHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMitral Valve InsufficiencyMyocardial InfarctionPlatelet Aggregation InhibitorsPrognosisProspective StudiesSeverity of Illness IndexStentsSurvival AnalysisTreatment OutcomeConceptsAcute myocardial infarctionLeft ventricular ejection fractionMechanical reperfusion therapySevere mitral regurgitationMitral regurgitationIndex procedureReperfusion therapyIndependent predictorsMyocardial infarctionLate Angioplasty Complications (CADILLAC) trialPresence of MRHigher Killip classMechanical reperfusion strategiesNon-shock patientsHigh-risk patientsLong-term mortalityTriple vessel diseasePercutaneous coronary interventionVentricular ejection fractionMild mitral regurgitationControlled AbciximabKillip classReperfusion strategyComplications TrialCoronary intervention
2003
Baseline features and clinical results in patients excluded from randomization from a large international trial of reperfusion strategies in acute myocardial infarction: The CADILLAC Registry
Turco M, Cox D, Garcia E, Tcheng J, Griffin J, Guagliumi G, Stuckey T, Carroll J, Grines C, Rutherford B, Slack S, Fahy M, Mehran R, Lansky A, Stone G. Baseline features and clinical results in patients excluded from randomization from a large international trial of reperfusion strategies in acute myocardial infarction: The CADILLAC Registry. Journal Of The American College Of Cardiology 2003, 41: 368. DOI: 10.1016/s0735-1097(03)82163-0.Peer-Reviewed Original Research
2002
Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction
Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ. Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction. New England Journal Of Medicine 2002, 346: 957-966. PMID: 11919304, DOI: 10.1056/nejmoa013404.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryAntibodies, MonoclonalCombined Modality TherapyCoronary AngiographyFemaleHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMyocardial InfarctionMyocardial ReperfusionPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRecurrenceStentsStrokeConceptsPrimary percutaneous transluminal coronary angioplastyAcute myocardial infarctionPercent of patientsPrimary end pointInfarct-related arteryRate of deathMyocardial infarctionAbciximab therapyReperfusion strategyPlatelet glycoprotein IIb/IIIa inhibitorsGlycoprotein IIb/IIIa inhibitorsTarget vesselIIb/IIIa inhibitorsPercutaneous transluminal coronary angioplastyEnd pointComposite of deathTarget vessel revascularizationIschemia-driven revascularizationTransluminal coronary angioplastyComparison of AngioplastyAbciximab useRecurrent ischemiaExperienced centersCoronary angioplastyCoronary stenting
2000
Thrombolytic therapy in older patients
Berger A, Radford M, Wang Y, Krumholz H. Thrombolytic therapy in older patients. Journal Of The American College Of Cardiology 2000, 36: 366-374. PMID: 10933344, DOI: 10.1016/s0735-1097(00)00723-3.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionPrimary angioplastyThrombolytic therapyOlder patientsBundle branch blockAcute reperfusionBranch blockST-segment elevationPatients age 65Population-based cohortReperfusion strategyReperfusion therapyHospital arrivalSurvival benefitSymptom onsetSegment elevationPhysician factorsST elevationMyocardial infarctionNational cohortAngioplastyBetter survivalMedicare beneficiariesLower mortalityPatients
1998
Use and Effectiveness of Intravenous Heparin Therapy for Treatment of Acute Myocardial Infarction in the Elderly
Krumholz H, Hennen J, Ridker P, Murillo J, Wang Y, Vaccarino V, Ellerbeck E, Radford M. Use and Effectiveness of Intravenous Heparin Therapy for Treatment of Acute Myocardial Infarction in the Elderly. Journal Of The American College Of Cardiology 1998, 31: 973-979. PMID: 9561996, DOI: 10.1016/s0735-1097(98)00022-9.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionIntravenous heparin therapyIntravenous heparinMyocardial infarctionHeparin therapyMortality rateFull-dose intravenous heparinRetrospective cohort studyHospital medical recordsUse of heparinReperfusion strategyCohort studyElderly patientsMedical recordsBaseline differencesObservational studyMedicare beneficiariesInfarctionTherapeutic effectivenessPatientsTreatment factorsHeparinContraindicationsTreatmentTherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply